Join our Free Newsletter and unlock 50% off AltIndexFree newsletter + 50% offJoin free

Did Zenas BioPharma Beat Earnings?

Zenas BioPharma (ZBIO) reported Q2 '26 revenue of $1M.

AltIndex tracks earnings alongside 25+ alternative data signals that can move ahead of the report — Zenas BioPharma’s job postings, web traffic, and employee business outlook. See the full ZBIO stock analysis or the earnings calendar for upcoming reports.

Zenas BioPharma Quarterly Financial Trends ()

MetricQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Revenue—5M10M——10M—1M
Gross margin—100.0%100.0%——-557.2%—100.0%
Operating margin—-1,112.5%-373.3%——-2,379.8%—-10,765.9%
Net income-39M-53M-34M-52M-51M-240M-81M-111M
Net margin—-1,052.1%-335.7%——-2,404.4%—-11,145.6%
EPS————————

Zenas BioPharma Earnings Trend Analysis

Over the eight quarters from Q3 '24 to Q2 '26, Zenas BioPharma’s quarterly revenue moved from $0 to $1M.

When Is Zenas BioPharma’s Next Earnings Date?

Zenas BioPharma reports earnings on a quarterly schedule. Its most recent report covered Q2 '26. For the confirmed upcoming date — and every other company reporting soon — see the ZBIO earnings calendar.

Frequently Asked Questions: Zenas BioPharma Earnings

Zenas BioPharma's next earnings date has not been confirmed yet. See the earnings calendar for all upcoming reports.

Zenas BioPharma reported Q2 '26 revenue of $1M.

Signals like job postings, web traffic, and employee sentiment reflect business activity in real time and can move before quarterly results are reported. AltIndex combines them with 25+ others in the ZBIO AI Score.

The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.